Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Ramucirumab + Paclitaxel stomach cancer not applicable detail...
MAP2K1 Q56P Selumetinib stomach cancer sensitive detail...
ERBB2 amp Lapatinib stomach cancer sensitive detail...
ERBB2 positive HER2 Vaccine stomach cancer sensitive detail...
ERBB2 positive Lapatinib + Paclitaxel stomach cancer sensitive detail...
ERBB2 positive Trastuzumab + Oxaliplatin stomach cancer sensitive detail...
Unknown unknown Saracatinib stomach cancer not applicable detail...
MET amp SAR125844 stomach cancer sensitive detail...
Unknown unknown Ramucirumab stomach cancer not applicable detail...
FGFR2 amp AZD4547 stomach cancer sensitive detail...
FGFR2 wild-type ERBB2 amp AZD4547 stomach cancer resistant detail...
KRAS mutant BAY1082439 stomach cancer decreased response detail...
KRAS mutant BKM120 + AG490 stomach cancer sensitive detail...
KRAS G12D BKM120 + AG490 stomach cancer sensitive detail...
Unknown unknown Deguelin + Cisplatin stomach cancer not applicable detail...
Unknown unknown RX-0201 stomach cancer not applicable detail...
Unknown unknown CUDC-101 stomach cancer not applicable detail...
Unknown unknown JNJ-26483327 stomach cancer not applicable detail...
KRAS mutant Poziotinib stomach cancer resistant detail...
ERBB2 over exp S-222611 stomach cancer sensitive detail...
ERBB2 over exp trastuzumab + varlitinib stomach cancer sensitive detail...
ERBB2 over exp Tucatinib stomach cancer sensitive detail...
ERBB2 over exp varlitinib stomach cancer sensitive detail...
ERBB2 over exp TAK-285 stomach cancer sensitive detail...
Unknown unknown Sapitinib + Fluorouracil + Cisplatin stomach cancer not applicable detail...
ERBB2 over exp Lapatinib stomach cancer sensitive detail...
ERBB2 amp ERBB2 over exp Afatinib stomach cancer sensitive detail...
ERBB2 over exp Dacomitinib stomach cancer sensitive detail...
ERBB2 amp Poziotinib stomach cancer sensitive detail...
ERBB2 amp BMS-690514 stomach cancer sensitive detail...
ERBB2 over exp BMS-690514 stomach cancer sensitive detail...
ERBB2 over exp Paclitaxel + Trastuzumab + MM-111 stomach cancer sensitive detail...
ERBB2 over exp CDX-3379 stomach cancer sensitive detail...
ERBB2 over exp trastuzumab emtansine stomach cancer sensitive detail...
ERBB2 amp ERBB2 over exp trastuzumab emtansine stomach cancer sensitive detail...
ERBB2 over exp MM-302 stomach cancer predicted - sensitive detail...
PTEN del CH5132799 stomach cancer sensitive detail...
ERBB2 amp Trastuzumab stomach cancer sensitive detail...
ERBB2 amp Trastuzumab + Lapatinib stomach cancer sensitive detail...
FGFR2 wild-type Ponatinib stomach cancer resistant detail...
FGFR2 amp Ponatinib stomach cancer sensitive detail...
FGFR2 amp Dovitinib stomach cancer sensitive detail...
FGFR2 amp Cediranib stomach cancer sensitive detail...
FGFR2 amp Brivanib stomach cancer no benefit detail...
ERBB2 over exp KU004 stomach cancer sensitive detail...
CDH1 mutant N/A stomach cancer not applicable detail...
MET amp TAE226 stomach cancer sensitive detail...
FGFR2 amp FIIN-01 stomach cancer sensitive detail...
FGFR2 amp Selumetinib stomach cancer resistant detail...
FGFR2 amp PD173074 stomach cancer sensitive detail...
FGFR2 amp BGJ398 stomach cancer sensitive detail...
FGFR2 amp FF-284 stomach cancer sensitive detail...
KRAS G12D MET over exp Crizotinib stomach cancer resistant detail...
MET over exp Crizotinib stomach cancer sensitive detail...
FGFR2 amp PRN1109 stomach cancer predicted - sensitive detail...
SMO wild-type Vismodegib stomach cancer predicted - sensitive detail...
MET over exp KRC-00715 stomach cancer sensitive detail...
MET over exp KRC-00509 stomach cancer sensitive detail...
MET amp TAS-115 stomach cancer sensitive detail...
Unknown unknown HD105 stomach cancer not applicable detail...
Unknown unknown AT13148 stomach cancer not applicable detail...
Unknown unknown Geldanamycin stomach cancer not applicable detail...
CBLB dec exp Fluorouracil stomach cancer decreased response detail...
MAP2K1 Q56P Trametinib stomach cancer sensitive detail...
NOTCH1 positive LY3039478 stomach cancer sensitive detail...
MET amp M-COPA stomach cancer sensitive detail...
Unknown unknown LY3164530 stomach cancer not applicable detail...
Unknown unknown Lapatinib + Capecitabine stomach cancer not applicable detail...
Unknown unknown Apatinib stomach cancer not applicable detail...
ATM dec exp Veliparib stomach cancer sensitive detail...
MET amp FF-284 stomach cancer no benefit detail...
MET amp KTN0073-IgG2 stomach cancer sensitive detail...
Unknown unknown Cetuximab stomach cancer no benefit detail...
Unknown unknown Everolimus stomach cancer no benefit detail...
Unknown unknown Bevacizumab stomach cancer not applicable detail...
Unknown unknown Irinotecan + Nimotuzumab stomach cancer no benefit detail...
Unknown unknown Regorafenib stomach cancer not applicable detail...
Unknown unknown Olaparib + Paclitaxel stomach cancer conflicting detail...
ATM dec exp Olaparib + Paclitaxel stomach cancer predicted - sensitive detail...
Unknown unknown Ipilimumab stomach cancer no benefit detail...
Unknown unknown Avelumab stomach cancer not applicable detail...
Unknown unknown Nivolumab stomach cancer not applicable detail...
Unknown unknown Nivolumab + Ipilimumab stomach cancer not applicable detail...
ERBB2 positive DS-8201a stomach cancer sensitive detail...
MET amp AMG 337 stomach cancer sensitive detail...
Unknown unknown PU-H71 stomach cancer not applicable detail...
FGFR2 positive BAY1187982 stomach cancer sensitive detail...
FGFR2 amp E7090 stomach cancer sensitive detail...
MET amp SGX523 stomach cancer sensitive detail...
MET over exp Merestinib stomach cancer sensitive detail...
ATM over exp Veliparib stomach cancer decreased response detail...
ATM over exp Irinotecan + Veliparib stomach cancer sensitive detail...
ATM over exp Irinotecan stomach cancer decreased response detail...
MET amp ARGX-111 stomach cancer sensitive detail...
MET amp Telisotuzumab vedotin stomach cancer sensitive detail...
FGFR2 amp FGFR2 over exp BGJ398 stomach cancer sensitive detail...
FGFR2 amp FGFR2 over exp AZD4547 stomach cancer sensitive detail...
MET amp over exp Altiratinib stomach cancer sensitive detail...
MET over exp MET Y1230H PHA-665752 stomach cancer resistant detail...
MET over exp MET Y1230C PHA-665752 stomach cancer resistant detail...
MET over exp MET Y1230C MET Y1230H Crizotinib stomach cancer resistant detail...
Unknown unknown Chiauranib stomach cancer not applicable detail...
ERBB2 positive MGAH22 stomach cancer predicted - sensitive detail...
Unknown unknown AZD6738 + Paclitaxel stomach cancer not applicable detail...
Unknown unknown AZD6738 + Cisplatin stomach cancer not applicable detail...
MET amp Golvatinib stomach cancer sensitive detail...
ERBB2 over exp MM-302 + Trastuzumab stomach cancer sensitive detail...
Unknown unknown Doxorubicin + Tozasertib stomach cancer not applicable detail...
Unknown unknown OPB-111077 stomach cancer not applicable detail...
FGFR2 amp Erdafitinib stomach cancer sensitive detail...
ERBB2 over exp HER2 CAR-T cells stomach cancer sensitive detail...
Unknown unknown LY2874455 stomach cancer not applicable detail...
MET Y1230C Capmatinib stomach cancer resistant detail...
MET Y1230C Crizotinib stomach cancer resistant detail...
MET F1200L MET Y1230H Crizotinib stomach cancer resistant detail...
MET F1200L MET Y1230H Capmatinib stomach cancer resistant detail...
MET Y1230C Glesatinib stomach cancer sensitive detail...
MET F1200L MET Y1230H Glesatinib stomach cancer sensitive detail...
FGFR2 amp TAS-120 stomach cancer predicted - sensitive detail...
FGFR3 positive Rogaratinib stomach cancer predicted - sensitive detail...
ERBB2 positive ZW25 stomach cancer predicted - sensitive detail...
Unknown unknown DKN-01 + Paclitaxel stomach cancer not applicable detail...
MET del exon14 Glesatinib stomach cancer sensitive detail...
MET amp Glesatinib stomach cancer sensitive detail...
MET over exp SYM015 stomach cancer sensitive detail...
MET del exon14 SYM015 stomach cancer sensitive detail...
MET del exon14 Emibetuzumab stomach cancer decreased response detail...
ATM negative Olaparib + Paclitaxel stomach cancer no benefit detail...
ERBB2 over exp MET amp Trastuzumab stomach cancer predicted - resistant detail...
ERBB2 over exp MET amp MET R988C Trastuzumab stomach cancer predicted - resistant detail...
ERBB2 over exp KRAS G13D Trastuzumab stomach cancer predicted - resistant detail...
BRAF V600E ERBB2 over exp KRAS A146V Trastuzumab stomach cancer predicted - resistant detail...
ERBB2 positive MEDI4276 stomach cancer predicted - sensitive detail...
MET amp SCC244 stomach cancer sensitive detail...
ERBB2 positive MI130004 stomach cancer sensitive detail...
STK11 mutant N/A stomach cancer not applicable detail...
SMAD4 mutant N/A stomach cancer not applicable detail...
MLH1 mutant N/A stomach cancer not applicable detail...
FGFR2 amp FGFR2 fusion Derazantinib stomach cancer sensitive detail...
FGFR2 amp Derazantinib stomach cancer sensitive detail...
Unknown unknown Camrelizumab stomach cancer not applicable detail...
Unknown unknown trifluridine/tipiracil hydrochloride stomach cancer not applicable detail...
ERBB2 positive ARX-788 stomach cancer sensitive detail...
KRAS over exp MET del exon14 Crizotinib stomach cancer predicted - resistant detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01325441 Phase Ib/II Napabucasin + Paclitaxel A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Recruiting
NCT01468922 Phase I Tivantinib Pazopanib Pazopanib and ARQ 197 for Advanced Solid Tumors Completed
NCT01522768 Phase II Afatinib + Trastuzumab Afatinib (BIBW 2992) and Trastuzumab in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer Recruiting
NCT01576666 Phase Ib/II BKM120 + Sonidegib Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors Completed
NCT01602406 Phase I LJM716 + Trastuzumab Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer Completed
NCT01641939 Phase III Docetaxel Paclitaxel trastuzumab emtansine A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer Terminated
NCT01702558 Phase II trastuzumab emtansine trastuzumab emtansine + Capecitabine A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Patients With HER2-Positive Metastatic Breast Cancer and Patients With HER2-Positive Locally Advanced / Metastatic Gastric Cancer Completed
NCT01928290 Phase II Trastuzumab FOLFIRINOX Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer Active, not recruiting
NCT01928394 Phase Ib/II Ipilimumab Nivolumab A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors Active, not recruiting
NCT01938638 Phase I BAY1143572 Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer Completed
NCT01968109 Phase I Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Recruiting
NCT02014909 Phase I CDX-3379 CDX-3379 + Vemurafenib CDX-3379 + Trastuzumab Cetuximab + CDX-3379 CDX-3379 + Erlotinib A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Completed
NCT02047747 Phase II Dacomitinib A Phase II Study of Dacomitinib in Progressive Brain Metastases Terminated
NCT02122809 Phase I Chiauranib Phase I Study of Chiauranib in Patients With Advanced Solid Tumors Completed
NCT02310464 Phase I OBI-821 + OBI-833 Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects Recruiting
NCT02314117 Phase III Capecitabine Fluorouracil Cisplatin Ramucirumab A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer Active, not recruiting
NCT02315066 Phase I PF-04518600 PF-04518600 + Utomilumab Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 Active, not recruiting
NCT02318901 Phase Ib/II Pembrolizumab + trastuzumab emtansine Pembrolizumab + Trastuzumab Pembrolizumab + Cetuximab Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer Terminated
NCT02323191 Phase I Atezolizumab LY3022855 A Study of RO5509554 and MPDL3280A Administered in Combination in Patients With Advanced Solid Tumors Recruiting
NCT02341625 Phase Ib/II BMS-986148 BMS-986148 + Nivolumab A Study of BMS-986148 in Patients With Select Advanced Solid Tumors Active, not recruiting
NCT02346955 Phase I CM-24 CM-24 + Pembrolizumab Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) Terminated
NCT02393248 Phase Ib/II Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Epacadostat + Pembrolizumab Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies Recruiting
NCT02404441 Phase Ib/II PDR001 Phase I/II Study of PDR001 in Patients With Advanced Malignancies Active, not recruiting
NCT02443883 Phase II Ramucirumab A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer Active, not recruiting
NCT02452424 Phase Ib/II Pembrolizumab + Pexidartinib A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors Completed
NCT02460224 Phase Ib/II LAG525 PDR001 Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Active, not recruiting
NCT02471846 Phase I GDC-0919 Atezolizumab A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors Active, not recruiting
NCT02500199 Phase I Pyrotinib Open Label Oral Use of Pyrotinib in Patients With HER2 Positive Solid Tumors Who Failed Prior HER2 Targeted Therapy Recruiting
NCT02559492 Phase I INCB039110 + INCB024360 INCB039110 + INCB050465 INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors Active, not recruiting
NCT02575781 Phase I SAR428926 A Study of SAR428926 in Patients With Advanced Solid Tumors Completed
NCT02631733 Phase I Irinotecan + Veliparib Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Suspended
NCT02646748 Phase I INCB050465 Pembrolizumab Itacitinib Pembrolizumab Combined With INCB039110 and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Recruiting
NCT02658214 Phase I Carboplatin + Gemcitabine Carboplatin + nab-paclitaxel Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Durvalumab + Tremelimumab Paclitaxel + Carboplatin Carboplatin + Etoposide Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors Active, not recruiting
NCT02660034 Phase I BGB-A317 + Pamiparib The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors Recruiting
NCT02734004 Phase Ib/II Durvalumab + Olaparib A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA) Recruiting
NCT02760797 Phase I Emactuzumab + RO7009789 A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors Completed
NCT02872116 Phase III Capecitabine + Oxaliplatin Nivolumab + Ipilimumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Efficacy Study of Nivolumab Plus Ipilimumab Against Chemotherapy Standard of Care in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649) Recruiting
NCT02880371 Phase Ib/II ARRY-382 + Pembrolizumab A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors Recruiting
NCT02935634 Phase II Nivolumab + Relatlimab Nivolumab + Ipilimumab A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer (FRACTION-GC) Recruiting
NCT02952248 Phase I BI 754091 A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours Recruiting
NCT02952729 Phase I XMT-1522 Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 Active, not recruiting
NCT02960594 Phase I INO-1400 + INO-9012 INO-1400 hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Completed
NCT02963831 Phase Ib/II ONCOS-102 + MEDI4736 A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Recruiting
NCT02965885 Phase I TAS-116 A Study of TAS-116 in Patients With Solid Tumors Active, not recruiting
NCT02970539 Phase I Oraxol + Ramucirumab Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers Recruiting
NCT03126110 Phase Ib/II INCAGN01876 + Nivolumab + Ipilimumab INCAGN01876 + Nivolumab INCAGN01876 + Ipilimumab Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies Recruiting
NCT03132922 Phase I Autologous MAGE-A4 C1032 TCR-modified T cells MAGE-A4c1032T for Multi-Tumor Recruiting
NCT03284723 Phase I PF-06804103 PF-06804103 Dose Escalation in HER2 Positive Solid Tumors Recruiting
NCT03319459 Phase I FATE-NK100 FATE-NK100 + Trastuzumab Cetuximab + FATE-NK100 FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors Recruiting
NCT03329950 Phase I CDX-1140 + CDX-301 CDX-1140 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors Recruiting
NCT03330561 Phase I PRS-343 PRS-343 in HER2-Positive Solid Tumors Recruiting
NCT03342417 Phase II Nivolumab + Ipilimumab Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients Recruiting
NCT03448042 Phase I BTRC 4017A A Phase I Study of BTRC4017A in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers Recruiting
NCT03505320 Phase II IMAB362 Claudiximab + FOLFOX A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of IMAB362 in Participants With Claudin (CLDN) 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma Recruiting
NCT03511222 Phase I Pembrolizumab + Vorolanib Nivolumab + Vorolanib Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors Recruiting
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Recruiting
NCT03568539 Phase Ib/II Sintilimab IBI308 in Subjects With Advanced/Metastatic Solid Malignancies Recruiting
NCT03596372 Phase I BAY1834942 Study of BAY1834942 in Patients With Solid Tumors Recruiting
NCT03602079 Phase Ib/II A166 Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene Recruiting
NCT03610711 Phase Ib/II Nivolumab + Relatlimab Nivolumab REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer (REACTION) Not yet recruiting
NCT03621982 Phase I Camidanlumab Tesirine Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Recruiting
NCT03662659 Phase II Nivolumab + Relatlimab + TS-1 FOLFOX + Nivolumab + Relatlimab Nivolumab + TS-1 Capecitabine + Nivolumab + Oxaliplatin Nivolumab + mFOLFOX-6 Capecitabine + Nivolumab + Oxaliplatin + Relatlimab An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers Recruiting
NCT03674567 Phase Ib/II FLX475 + Pembrolizumab FLX475 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Recruiting
NCT03700294 Phase I ADCT-601 Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors Recruiting
NCT03704077 Phase II Nivolumab Ramucirumab + Paclitaxel Nivolumab + Paclitaxel Nivolumab + Paclitaxel + Relatlimab Nivolumab + Relatlimab An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Trherapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cance or Gastroesophageal Junction Adenocarcinoma Not yet recruiting
NCT03720678 Phase I AB928 + mFOLFOX-6 A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Gastrointestinal (GI) Malignancies Recruiting
NCT03775850 Phase Ib/II EDP1503 EDP1503 + Pembrolizumab A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors Recruiting
NCT03829501 Phase Ib/II Atezolizumab + KY1044 KY1044 Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer Recruiting